Treatment of Recurrent Vulvovaginal Candidiasis

Initial Management Approach

• For recurrent vulvovaginal candidiasis (RVVC), defined as ≥4 episodes per year, the Centers for Disease Control and Prevention recommends treating with 10-14 days of induction therapy using either a topical azole or oral fluconazole, followed by fluconazole 150 mg weekly for 6 months as maintenance therapy 1
• Obtain vaginal cultures to confirm clinical diagnosis and identify the Candida species, particularly to detect non-albicans species like C. glabrata (found in 10-20% of RVVC cases) 2, 3, 4
• Most RVVC cases are caused by azole-susceptible C. albicans 5

Induction Phase

• The induction phase should last 10-14 days 1
• Topical azole therapy for 10-14 days is an option (any topical agent; no superiority of one over another) 1
• Oral fluconazole 150 mg every 72 hours for 2-3 doses is an alternative option 2, 6

Maintenance Therapy

• The primary recommendation for maintenance therapy is fluconazole 150 mg once weekly for 6 months 1, 5
• Alternative maintenance regimens include clotrimazole 500 mg vaginal suppository once weekly, itraconazole 400 mg once monthly or 100 mg once daily, and ketoconazole 100 mg once daily (monitor for hepatotoxicity; 1 in 10,000-15,000 risk) 2, 6

Management of Non-Albicans Species

• For C. glabrata infections unresponsive to oral azoles, the first-line treatment is boric acid 600 mg intravaginal gelatin capsule daily for 14 days (70% eradication rate) 7, 6, 4
• Second-line treatment options include nystatin 100,000 units intravaginal suppository daily for 14 days and topical 17% flucytosine cream ± 3% amphotericin B cream daily for 14 days 7, 1

Important Clinical Caveats

• Partner treatment is not routinely recommended, but may be considered in women with persistent recurrences or symptomatic balanitis in male partners 2, 6
• Women with higher numbers of episodes before treatment, longer duration of disease, or presence of Candida non-albicans species during maintenance are more likely to fail maintenance therapy 6
• Fluconazole is generally well tolerated, but serious hepatic reactions are rare and drug interactions can occur with certain medications 2, 8
• Special populations, such as pregnant women, HIV-infected women, and women with diabetes or immunosuppression, require tailored treatment approaches 2, 4, 5

Evaluation of Recurrent Vulvovaginal Candidiasis

Diagnostic Approaches

• Consider PCR testing, as it demonstrates superior sensitivity (90.9%) and specificity (94.1%) compared to microscopy alone (sensitivity 57.5%, specificity 89.4%) in patients with recurrent vulvovaginal candidiasis 9

Underlying Conditions to Evaluate

• Screen for diabetes mellitus, as uncontrolled diabetes significantly impairs treatment response and requires 7-14 days of therapy rather than short courses, according to the Centers for Disease Control and Prevention 10
• Assess HIV status in appropriate clinical contexts, as HIV-infected women have higher colonization rates that correlate with immunosuppression severity, as recommended by the Centers for Disease Control and Prevention 10
• Evaluate for immunosuppression, including corticosteroid use or other debilitating medical conditions that reduce response to short-term therapies, as suggested by the American Academy of Family Physicians 11
• Assess for pregnancy, as vulvovaginal candidiasis commonly occurs during pregnancy and requires topical-only therapy for 7 days, according to the American College of Obstetricians and Gynecologists 10

Diagnostic Pitfalls to Avoid

• Recognize that standard laboratory susceptibility testing at pH 7 underestimates resistance, as all antifungals have significantly higher MICs at vaginal pH 4, as reported in Clinical Infectious Diseases 12

Host Factor Assessment

• Systematic evaluation for modifiable conditions, such as genetic predisposition or underdosing, remains essential before attributing recurrence to idiopathic causes, as suggested by the Infectious Diseases Society of America 12

CDC Recommendations for Management of Recurrent Vulvovaginal Candidiasis

Safety and Adverse Effects

• Hepatotoxicity risk of ketoconazole: Daily oral ketoconazole 100 mg carries a liver‑toxicity risk estimated at 1 case per 10,000–15,000 patients. 13

Partner Management

• Partner treatment guidance: Routine treatment of male partners is not advised, but it may be considered when a woman experiences persistent recurrences or when the male partner has symptomatic balanitis. 13

Drug‑Drug Interactions

• Fluconazole interaction profile: Fluconazole can interact with a broad range of medications, including astemizole, calcium‑channel antagonists, cisapride, warfarin, cyclosporine, oral hypoglycemics, phenytoin, protease inhibitors, tacrolimus, terfenadine, theophylline, and rifampin. Clinicians should review concomitant drugs before initiating fluconazole therapy. 13

Pregnancy Considerations

• Therapeutic restrictions in pregnancy: For pregnant patients, only topical azole agents should be used, limited to a 7‑day course. All oral azoles, fluconazole, and intravaginal boric acid are contraindicated during pregnancy. 13

Underlying Risk Factors

• Impact of recent antibiotic use: Recent or repeated courses of systemic antibiotics are identified as a modifiable underlying condition that can predispose to recurrent vulvovaginal candidiasis. 13

Follow‑Up Monitoring

• Recommended follow‑up strategy: Patients receiving maintenance therapy should be monitored regularly for efficacy and adverse effects. A repeat vaginal culture is advised 1 month after completing therapy to confirm mycological cure, especially in cases caused by Candida glabrata. 13